Treekitkarnmongkol, Warapen https://orcid.org/0000-0002-7542-5201
Katayama, Hiroshi https://orcid.org/0000-0003-1821-0260
Sankaran, Deivendran https://orcid.org/0000-0001-5837-2083
Tai, Mei-Chee
Rauth, Sanchita
Chen, Hanxiao
Nguyen, Tristian https://orcid.org/0009-0000-4565-1534
Hara, Kieko
Thege, Fredrik I. https://orcid.org/0000-0002-1822-4526
Ponnusamy, Moorthy P.
Batra, Surinder K. https://orcid.org/0000-0001-9470-9317
Wang, Huamin https://orcid.org/0000-0002-2038-5863
Wistuba, Ignacio I.
Schmittgen, Thomas D. https://orcid.org/0000-0002-2812-8546
Heymach, John V. https://orcid.org/0000-0001-9068-8942
Kopetz, Scott https://orcid.org/0000-0001-9647-3416
Hu, Tony
Yao, Wantong
Maitra, Anirban https://orcid.org/0000-0001-7923-9978
Sen, Subrata https://orcid.org/0000-0001-6884-6246
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01 CA214263)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01 CA252965)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
The Sheikh Khalifa bin Zayed Foundation
Article History
Received: 17 July 2024
Accepted: 23 October 2025
First Online: 1 December 2025
Competing interests
: A.M. is a consultant for Tezcat Bioscience. A.M. is listed on a patent that had been licensed by Thrive Earlier Detection (an Exact Sciences Company). K.H. is funded by Nanostring Technology. The other authors declare no competing interests. A provisional patent on the clinically relevant findings of this study has been filed.